RGEN: Repligen Corporation Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 7, 11:04 AM Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however, led by strength in its bioprocessing business and higher royalty revenue from Bristol-Myers Squibb (BMY) and Pfizer (PFE). looking forward, the company see FY13 net income coming in around $18M - $20M. 1 Comment [Healthcare, Earnings]
Thursday, March 7, 7:37 AM Repligen (RGEN): Q4 EPS of $0.30. Revenue of $18.8M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, June 22, 2012, 8:58 AM Repligen (RGEN) -20.3% premarket after the FDA confirms the biotech company must conduct further trials before potentially getting approval for its RG1068 synthetic human secretin used to detect pancreatic-duct abnormalities in patients with pancreatitis. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 11:44 AM Repligen (RGEN -0.3%) shareholder Ronald L. Chez says that after speaking to Board Chairperson Karen Dawes, he plans to call as special meeting to discuss reducing the number of shares outstanding in the company and other strategic alternatives for the company on the back of recent developments in its new drug application for RG1068. 1 Comment [Healthcare]
Thursday, April 26, 2012, 11:12 AM Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee meeting to review the company's new-drug application for its pancreatitis drug RG1068. The drug developer says it expects the FDA to request additional clinical-trial data. 1 Comment [Healthcare, On the Move]
Tuesday, February 21, 2012, 8:59 AM The FDA grants priority review for Repligen's (RGEN) SecreFlo product used to help detect pancreatic cancer in MRIs. If approved, the firm estimates 300K MRI procedures a year could use the noninvasive method of evaluating patients. Shares +9.2% premarket. 1 Comment [On the Move, Healthcare]
Wednesday, December 21, 2011, 8:10 AM Repligen (RGEN) announces the submission of a New Drug Application for SecreFlo, including a request to receive priority review by the FDA. The firm says it plans to release initial results from a study on the ability of SecreFlo to detect pancreatic cancer in the first half of 2012. Comment! [Healthcare]
Thursday, June 23, 2011, 4:17 PM Repligen's (RGEN +5%) jumps after its spinal muscular atrophy drug gets a fast-track designation from the FDA, and a postive opinion for orphan status from the European Medicines Agency. Comment! [Healthcare]
Monday, March 7, 2011, 9:05 AM Premarket gainers: TOMO +23%. JRCC +12%. RAME +12%. STX +11%. WDC +11%. AVL +7%. QTM +7%. EXK +7%. DPTR +6%. SSN +6%. SVVS +6%. GPL +5%. PZG +4%. SHZ +4%. OCZ +4%. GMXR +4%. VLNC +4%. MCP +4%. ICO +4%. BQI +4%. SVM +3%. SLW +3%. PHYS +3%.
Losers: RGEN -25%. CTIC -8%. ARAY -7%. CIEN -4%. JOE -3%. Comment!

RGEN Repligen Corporation

RGEN

Repligen Corporation